Considering the broader genetic background, pharmacogenomic variability may further contribute to treatment heterogeneity, as genetic variants affecting GLP-1 receptor signaling, appetite regulation, insulin secretion, and hostmicrobiota interactions could influence individual responsiveness (126)
KD may increase the NAD + /NADH ratio through various mechanisms
GLP-1 receptor agonist therapy should be considered in all patients with type II diabetes and elevated ASCVD risk regardless of A1c or current hyperglycemic therapy
If the results are low, or even at the low end of the normal range, cobalamin supplementation is called for
This is counterfeit medicine wrapped inside counterfeit authority
#Obesity #GLP1 #MASH #Biopharma #DrugDevelopment To view or add a comment, sign in At PharmaGambit we talk a lot about competitor reactions, strategic positioning and why markets rarely play out how companies expect